News
Could Novo Nordisk's Wegovy-fuelled run of hiking sales guidance be ending?
STORY: Since launching its popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several times a year.But recent weak U.S. prescription data is leading some investors and analysts to question whether its stellar run is coming to an end.
Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Novo Nordisk partners with telehealth ...
Now, alarmed by sunken features and sagging skin, newly svelte patients are flooding med spas and plastic surgery clinics, desperate to plump, lift and smooth their way back to a youthful glow. These ...
Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...
Eli Lilly and Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot.
Futurism on MSN11d
Novo Nordisk Is Getting Absolutely DestroyedShares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.
Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.
The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...
Former Playboy star Kendra Wilkinson revealed that she started taking a weight-loss drug but threw the medication away after ...
The former Playboy model, 39, started injecting the drug after being body-shamed by internet trolls earlier this year.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback